Human CTLA-4 Antibody from MYBIOSOURCE INC.

Search, find, compare suppliers for anti-Human CTLA-4 antibody, protein, ELISA kits.

Edit 
Antigenic SpecificityHuman CTLA-4
Clone[A3.4H2.H12]
Host SpeciesMouse
Reactive Specieshuman
IsotypeIgG2ak
Formatfluorescein (FITC) conjugate
Size0.1 mg
ConcentrationAntibody concentration: 0.1 mg/ml
ApplicationsFlow Cytometry (FC/FACS)
Reviews / RatingsIf you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
DescriptionSpecificity: Human CTLA-4 (CD152). Human CTLA-4 (also known as Cytotoxic T lymphocyte-associated antigen-4, CD152) is a structural homologue of T cell co-stimulatory receptor CD28. CTLA-4 binds to the same ligands (CD80 and CD86) as CD28 but with much higher avidity. It is expressed at very low levels on the cell surface of activated T cells, and is found primarily in the post-Golgi or endosomal compartments of the cell. There is a high degree of overall homology between human and mouse CTLA-4 (>70%), and the cytoplasmic domains of the human, mouse and rabbit sequences are completely conserved. CD152 antibodies have shown both stimulatory and negative regulatory roles in functional experiments. This antibody is suitable for use in Intracell
ImmunogenImmunogen: Activated T cells. Donor: Balb/c mouse. Fusion Partner:. SP 2/0 myeloma
Other Names[CTLA-4, FITC, (clone: A3.4H2.H12), (mouse IgG2ak); FITC Human CTLA-4 (CD152)], [CTLA4; CTLA4; CD; GSE; GRD4; CD152; CTLA-4; IDDM12; CELIAC3; CD152; CTLA-4]
Gene, Accession #[CTLA-4], Gene ID: 1493, NCBI: NP_005205.2, UniProt: P16410
Catalog #MBS520258
Price$290
Order / More InfoHuman CTLA-4 Antibody from MYBIOSOURCE INC.
Product Specific Referencesn/a
MYBIOSOURCE INC.
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166

sales@mybiosource.com

http://www.MyBioSource.com

Profile of MYBIOSOURCE INC.
Return to Antibodies

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.